MENLO
PARK, Calif., Jan. 9, 2023
/PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of
highly accurate sequencing solutions, today announced a
collaboration with the University of
Tokyo, Graduate School of Medicine to study the use of
long-read sequencing and novel bioinformatics methods in the hopes
of better understanding the genetic causes of certain rare diseases
in individuals and cohorts within the Japanese population.
"Through this collaboration with the University of Tokyo, we plan on developing and
applying new methods in the hopes of identifying genetic mutations
of many diseases impacting the Japanese population," said
Michael Eberle, Vice President of
Computational Biology at PacBio. "This will help improve our
understanding of difficult genetic regions and variants that we
hope will benefit the Japanese population."
High-throughput bioinformatics software applications that are
optimized for PacBio HiFi long-read sequencing data, such as the
Tandem Repeat Genotyping Tool (TRGT), are designed to enable
researchers in Japan and the
international community to more effectively uncover
disease-associated variants, including structural variants such as
tandem repeats.
PacBio has worked with University of
Tokyo researchers for years and has assisted their work
around sequencing hundreds of human genomes and structural variants
associated with neurological disorders and leukemia (some of this
research was published in Nature Genetics in 2018 and
2019 and in Oxford Bioinformatics in 2016).
"Collaborating with PacBio in applying advanced bioinformatics
workflows should accelerate our in-progress work characterizing
structural variants and making these findings more accessible to
the broader scientific community. We believe this collaboration
will complement our previous work and help us identify many more
disease-causing structural variations in the human genome," said
Dr. Shoji Tsuji, a senior investigator for the University of Tokyo Hospital, Department of
Neurology.
About PacBio
Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a premier
life science technology company that is designing, developing, and
manufacturing advanced sequencing solutions to help scientists and
clinical researchers resolve genetically complex problems. Our
products and technology under development stem from two highly
differentiated core technologies focused on accuracy, quality, and
completeness which include our existing HiFi long-read sequencing
and our emerging SBB® short-read sequencing technologies. Our
products address solutions across a broad set of research
applications, including human germline sequencing, plant and animal
sciences, infectious disease and microbiology, oncology, and other
emerging applications. For more information, please visit
www.pacb.com and follow @PacBio.
Forward Looking
Statements
This press release may contain "forward-looking statements"
within the meaning of Section 21E of the Securities Exchange Act of
1934, as amended, and the U.S. Private Securities Litigation Reform
Act of 1995. All statements other than statements of historical
fact are forward-looking statements, including statements related
to the collaboration with and the University
of Tokyo, Graduate School of Medicine, the anticipated
outcomes and results of such collaboration, such as identifying
certain disease-causing variants associated with rare disease, and
other future events. Readers are cautioned not to place undue
reliance on these forward-looking statements and any such
forward-looking statements are qualified in their entirety by
reference to the following cautionary statements. All
forward-looking statements speak only as of the date of this press
release and are based on current expectations, and involve a number
of assumptions, risks and uncertainties that could cause the actual
results to differ materially from such forward-looking statements,
including, among others, potential product and quality issues, and
risks inherent in conducting a research study. Readers are strongly
encouraged to read the full cautionary statements contained in the
Company's filings with the Securities and Exchange Commission,
including the risks set forth in the company's Forms 8-K, 10-K, and
10-Q. The Company disclaims any obligation to update or revise any
forward-looking statements.
Contacts
Investors:
Todd Friedman
ir@pacificbiosciences.com
Media:
Lizelda Lopez
pr@pacificbiosciences.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/pacbio-and-the-university-of-tokyo-announce-bioinformatics-applications-collaboration-301715212.html
SOURCE Pacific Biosciences of California, Inc.